Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose lenalidomide for relapsed or refractory adult acute lymphoblastic leukaemia
ACTRN12613000993796Phase 2Withdrawn
- Sponsor
- Dr Sushrut Patil
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenalidomide in acute lymphoblastic leukemia (ALL), sponsored by Dr Sushrut Patil. Planned start Sep 2013; status: withdrawn.
02
Drugs
lenalidomide
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ACTRN12613000993796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000993796.